BACE1 and Alzheimer disease: A recent in vitro study demonstrated that nobiletin exhibits β-secretase (BACE1) inhibitory activity in a non-competitive manner with IC50 values of 5.9 × 10−5 M, suggesting it to be a promising BACE1 inhibitory agent to reduce Aβ production in AD [95].